Immune checkpoint inhibitor (ICI) therapy, especially programmed cell death 1/ligand 1 (PD‐1/PD‐L1) therapy, has been recommended as a first‐line treatment for non‐small cell lung cancer (NSCLC) [2]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.